Combining T cell therapy with a new treatment for HPV-related head and neck cancers

Who could benefit from this research

What this research studies

This research investigates a novel approach to treating head and neck cancers associated with human papillomavirus (HPV) by using genetically engineered T cells that target a specific HPV protein. The study aims to enhance the effectiveness of adoptive cell therapy by improving T cell persistence and reducing side effects. Patients will receive a low dose of these engineered T cells, which are designed to recognize and attack cancer cells expressing the HPV16 E7 antigen. The research will assess the safety and efficacy of this combined treatment strategy in patients with HPV-positive cancers.

Why it matters

Where this research is happening

• Yale University
  New Haven, United States Active

Researchers

• Principal investigator: Pai, Sara Isabel — Yale University
• Study coordinator: Pai, Sara Isabel

Related research

Other NIH-funded projects on the same topics.

• Targeting mitochondria with a ceramide compound to treat head and neck cancer

  A new drug candidate called LCL768 aims to kill head and neck cancer cells by targeting their mitochondria and could also boost how well immunotherapy works.

  NIH research Lipo-Immuno Tech, LLC · Mount Pleasant, United States · NIH-11404364

• How some p53 gene changes help head and neck cancers spread and hide from the immune system

  Researchers are looking at whether blocking a protein called MCM5 can stop p53‑mutant head and neck cancers from becoming unstable, spreading, and weakening the immune system.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11300228

• Combining Cue-101 and engineered T cells to treat HPV-positive head and neck cancer

  Doctors are combining Cue-101 with specially engineered T cells to help people with HPV16-positive head and neck cancer by improving tumor targeting while using lower cell doses.

  NIH research Yale University · New Haven, United States · NIH-11294142

• How mutations in the TP53 gene affect cancer spread and immune response in head and neck cancers

  This study is looking at certain changes in a gene called TP53 that are often found in head and neck cancers to see how they affect how the cancer grows and avoids the immune system, with the hope of finding new treatments that could work better for patients like you.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11034107

• Using nanoscale frameworks to enhance cancer treatment and immunotherapy for head and neck cancers

  This study is exploring a new way to help people with head and neck cancers by using tiny materials that can boost radiation therapy and help the immune system fight the cancer better, aiming to improve treatment results and survival rates for patients.

  NIH research University of Chicago · Chicago, United States · NIH-10885971

• Finding ways to improve immune responses in head and neck cancers

  This study is looking at ways to improve immunotherapy for people with head and neck cancer, aiming to help more patients respond to treatment by figuring out why the immune system sometimes doesn't fight the cancer effectively.

  NIH research Yale University · New Haven, United States · NIH-10690599

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.